

The December 20, 2021, article by Leavey et al entitled “Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children’s Oncology Group Report” (*J Clin Oncol* 10.1200/JCO.21.00358) was published with errors.

In Table 3, “SNM” was included in the list of abbreviations. The correct abbreviation is “**SMN**.”

In Figure 3A, the age group for the first line of the risk table was listed as > 17 years. It should have been **< 18 years**.

In Figure 3B, the age group for the first line of the risk table was listed as < 17 years. It should have been **< 18 years**.

This has been corrected as of June 7, 2022. The authors apologize for the errors.

DOI: <https://doi.org/10.1200/JCO.22.01234>



We are a global community of nearly 45,000 members from more than 150 countries, serving members from all subspecialties and professional roles in the pursuit of quality cancer care and progress. Membership provides the support, resources, and solutions for your professional needs:

- Stay on the cutting edge of scientific research and advances
- Streamline your pursuit of continuous learning
- Access evidence-based and data-driven quality resources
- Obtain insight into best practices for cancer care teams
- Connect and exchange views with oncology experts

To learn more about the value of membership, visit [asco.org/membership](https://www.asco.org/membership). Not a member? Join today at [join.asco.org](https://www.asco.org/join).